We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
IF at fifth you don't succeed - Pharmaphorum this time :-
https://pharmaphorum.com/news/gsk-begins-cancer-cell-therapy-tie-up-with-immatics/?
Bingo ?
The Company’s transformative product candidates are ? best in class ? Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’ proprietary and world-leading XPRESIDENT® technology. Together with Immatics’ powerful TCR discovery technology XCEPTOR®, these two platforms allow a full range of cancer therapies to be developed.
Immatics’ pipeline includes T-cell therapy programs based on the proprietary ACTolog®, ACTengine® and ACTallo® approaches, which are developed in collaboration through Immatics US with University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT), and several bispecific TCR and antibody molecules.
What is an ImmTAC® molecule?
ImmTAC® (Immune mobilising monoclonal TCRs against cancer) molecules are a new class of bi-specific biologics designed to overcome the limitations of other immuno-oncology agents by combining a T cell receptor (TCR)-targeting system with an anti-CD3 effector function to activate a highly potent and specific T cell response to cancer cells.
immunocore
its both as they have T cell redirect which is similar to immuncore system ie bi specific Mabs
similar to what Avidmab can do ...
There are 2 technologies involved here:
XCEPTOR and XPRESIDENT
XCEPTOR for discovering the targets
XPRESIDENT for validating the targets, whatever that means.
Does XPRESIDENT use TCells already activated for the target to do the validation?
https://clinicaltrials.gov/ct2/show/NCT02876510?term=IMA101&rank=1
This is the trial of interest, but if you look at the target antigens .. you will clearly see known antigens
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express collagen VI alpha 3 (COL6A3) exon 6, preferentially expressed antigen in melanoma (PRAME), melanoma-associated antigen 1 (MAGEA1), melanoma-associated antigen 4 (MAGEA4), melanoma-associated antigen 4 or 8 (MAGEA4/8), cancer/testis antigen 1A/New York esophageal squamous cell carcinoma 1 (CTAG1A/NY-ESO-1), or matrix remodeling-associated protein 5 (MXRA5).
The point i am making is Scancell had identified the targets and the epitopes .... but its still taken 2 years so far to get to clinic ready status ... ref TCR
Scancell also has all the Modi1 mouse data so is a far more advanced program ... as we have produced active CD4
Inanaco - agreed!
"The companies will collaborate on the identification, research and development of next-generation T-Cell Receptor (TCR) Therapeutics with a focus on solid tumors. The parties will initially develop autologous T-cell therapies with the option to add allogeneic cell therapies using Immatics’ ACTallo® approach. The companies intend to utilize proprietary TCRs identified by Immatics’ XCEPTOR® TCR discovery platform and directed against two proprietary targets, which were discovered and validated by Immatics’ XPRESIDENT® technology."
The 2 targets have been identified. I agree TF.
But it does sound like the collaboration is designed to find more targets.
Presumably more targets identified will result in more payments to Immatics but it wasn't specified.
Bermuda
That is what i said ..
"""Dont think it is ... £45m .. for two then £550m each ? ""
ie £45m is for two ........... then £550m each
your original post was
""""Total potential value of the deal is €550 plus milestones including an upfront payment of €46m. This sentence regarding timescales was interesting and perhaps relevant here:- """
so what we have agreed is 1 x £45 plus 2 x £550
but i do agree the wording is poor and its easily confused
Konar - I think it was concluded earlier that $50 million was for 2 targets identified and it seems that way to me. However, in the context of Scancell needing say $10 million funding this year, that looks handy enough. When's our turn ?
and that is how much you pay for someone just to identify a candidate. How much for an identified candidate that is proven pre-clinically to be very successful?
As I said - that's just two links - time for a snooze . . .
hTTp://european-biotechnology.com/up-to-date/latest-news/news/immatics-biotechnologies-lands-eur11bn-deal-with-gsk.html
There it is !
Shoot - oh for that edit function . . .
hTTps://www.businesswire.com/news/home/20200220005346/en/Immatics-GSK-Partner-Develop-Adoptive-Cell-Therapies
Thanks Inan and Bermuda - good luck to Immatics but when's our turn ?
Inanaco
This is another one of those occasions where we'll have to agree to differ. My understanding is that it's just one upfront payment of around €45m for the agreement to identify two TCR candidates and thereafter milestones of up to €550m per candidate. No matter, whichever way you look at it, it's a big deal.
I'd be a bit wary of applying those values to Moditope. At the moment it's enough just to see the demand for TCR therapies from big pharma manifesting itself in significant deals and all we can do is hope that Scancell are able to tap into that demand.
Dont think it is ... £45m .. for two then £550m each ?
regulatory and commercial milestone payments for ""each product"" as well as additional royalty payments.
well if modi1 is £2b or £1b ... at this junction i dont mind
Inanaco,
The wording from Immatic's own press announcement is perhaps a little clearer:-
'Under the terms of the agreement, Immatics will receive an upfront payment of 45 Million € (~$50 million) for two initial programs and is eligible to receive over $550M in development, regulatory and commercial milestone payments for each product as well as additional royalty payments.'
http://immatics.com/press-release/immatics-and-gsk-partner-to-develop-novel-adoptive-cell-therapies.html
Back in September 2019, this is where scancell were with their TCR program that had suffered a 6-month delay to the planned original timeline due to waiting for a Health and Safety approval which was approved:
'Lenti-viral transduction of T cells now working in the lab
40 TCRs recognising citrullinated/homocitrullinated epitopes to screen '
It is interesting that the TCR deal with BioNTech is for the use of modi1 only yet obviously modi2 is also being used.
Anyways I wonder where they are up to now!
Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive €46M upfront and €509M in undisclosed developmental and commercial milestone payments per program, plus royalties.
maybe wrong but it reads "per program"
Inanaco,
The upfront payment isn't per target - it's for the whole deal.
if you put that into perspective ....... modi1 is 4 targets ... 4 x £45m ...
Modi2 ?
Modi3 ?
That's to find the targets ... Bermuda , if you look at Lily Biontech 2015 to 2020 just to identify targets.
Scancell has those years already under its belt in effect 2012 to 2016 identifying the modi1 epitopes
so i would say the GSK project is possibly 6 years long ... from start to clinic
The Value of a Target ........... Tick Tock